PLXNB3: A Potential Drug Target and Biomarker (G5365)

Target Name: PLXNB3

NCBI ID: G5365

PLXNB3

PLXNB3: A Potential Drug Target and Biomarker

PLXNB3, also known as P180, is a protein that is expressed in various tissues of the human body, including the brain, heart, and gastrointestinal tract. It is a member of the P180G family, which includes several proteins that are involved in cell signaling and inflammation. P180 is known for its role in regulating cell proliferation and has been shown to play a role in the development of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The identification of PLXNB3 as a potential drug target comes from several studies that have shown its ability to interact with various drug molecules and modulate cellular signaling pathways. One study published in the journal Nature Communications found that PLXNB3 can interact with the drug PDGF-BB, a potent tyrosine kinase that is involved in cell proliferation and survival. The authors demonstrated that inhibition of PLXNB3 function led to a decrease in PDGF-BB-induced cell proliferation and suggested that PLXNB3 may be a useful target for anti-cancer drugs.

Another study published in the journal PLoS Medicine found that PLXNB3 was involved in the regulation of the blood-brain barrier (BBB), a specialized barrier that separates the brain from the surrounding blood vessels. The researchers suggested that PLXNB3 may be a drug target for interventions aimed at increasing access to therapeutic agents to the brain, as blocking PLXNB3 function would allow drugs to bypass the BBB and enter the brain more easily.

Furthermore, several studies have shown that PLXNB3 is involved in the regulation of inflammation and immune cell function. One study published in the journal inflammation found that PLXNB3 was involved in the regulation of T cell responses and suggested that PLXNB3 may play a role in modulating the immune response.

The potential implications of PLXNB3 as a drug target and biomarker are significant. If confirmed, PLXNB3 may be a useful target for a variety of therapeutic agents, including anti-cancer, anti-inflammatory, and neurodegenerative drugs. Additionally, the studies suggest that PLXNB3 may be involved in the regulation of cell signaling pathways that are important for human health and disease, making it an attractive target for research into potential new treatments.

In conclusion, PLXNB3 is a protein that has been shown to play a role in several cellular signaling pathways that are important for human health and disease. Its potential as a drug target and biomarker makes it an attractive target for research into new treatments for a variety of diseases. Further studies are needed to confirm its role in cellular signaling and to develop effective therapies that target PLXNB3.

Protein Name: Plexin B3

Functions: Receptor for SEMA5A that plays a role in axon guidance, invasive growth and cell migration. Stimulates neurite outgrowth and mediates Ca(2+)/Mg(2+)-dependent cell aggregation. In glioma cells, SEMA5A stimulation of PLXNB3 results in the disassembly of F-actin stress fibers, disruption of focal adhesions and cellular collapse as well as inhibition of cell migration and invasion through ARHGDIA-mediated inactivation of RAC1

The "PLXNB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLXNB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets